IQVIA (NYSE:IQV) Given New $256.00 Price Target at Robert W. Baird

IQVIA (NYSE:IQV) had its price objective raised by Robert W. Baird from $251.00 to $256.00 in a report issued on Friday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

A number of other analysts have also recently weighed in on the stock. Jefferies Financial Group cut shares of IQVIA from a buy rating to a hold rating and reduced their target price for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Barclays boosted their target price on shares of IQVIA from $255.00 to $275.00 and gave the company an overweight rating in a research note on Tuesday, July 23rd. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the stock an overweight rating in a research note on Tuesday, July 23rd. UBS Group lifted their target price on IQVIA from $295.00 to $300.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. Finally, Evercore ISI increased their target price on shares of IQVIA from $230.00 to $270.00 and gave the stock an outperform rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $267.00.

IQVIA Stock Down 0.6 %

Shares of NYSE:IQV opened at $240.75 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA has a 1-year low of $167.42 and a 1-year high of $261.73. The company’s fifty day moving average is $240.90 and its two-hundred day moving average is $233.81. The stock has a market capitalization of $43.86 billion, a price-to-earnings ratio of 32.89, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.22 earnings per share. Equities analysts anticipate that IQVIA will post 10.25 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently modified their holdings of IQV. Jennison Associates LLC grew its stake in IQVIA by 7.3% in the first quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after purchasing an additional 9,578 shares in the last quarter. Cadian Capital Management LP bought a new stake in IQVIA during the fourth quarter worth $70,108,000. Nomura Holdings Inc. acquired a new stake in IQVIA in the fourth quarter valued at $857,000. PGGM Investments grew its position in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the period. Finally, Fiduciary Alliance LLC acquired a new position in shares of IQVIA during the 1st quarter worth about $1,864,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.